N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: The Edinburgh type 2 diabetes study

Diabetologia

Volumn 57, Issue 12, 2014, Pages 2505-2512

  Price, Anna H ^a   Welsh, Paul ^b   Weir, Christopher J ^a,c   Feinkohl, Insa ^a   Robertson, Christine M ^a   Morling, Joanne R ^a   McLachlan, Stela ^a   Strachan, Mark W J ^d   Sattar, Naveed ^b   Price, Jackie F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Edinburgh Health Services Research Unit   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Epidemiology; NT proBNP; Risk prediction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; RISK FACTOR; VASCULAR ACCESS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84926639494     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3375-9     Document Type: Article

References (27)

1. Emerging Risk Factors Collaboration (2012) C-reactive protein, fi-brinogen, and cardiovascular disease prediction. N Engl J Med 367: 1310–1320
2. Rydén L, Grant P, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 34:3035–3087
3. Welsh P, Doolin O, Willeit P et al (2013) N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J 34:443–450
4. Wannamethee SG, Welsh P, Lowe GD et al (2011) N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 58:56–64
5. Linssen GCM, Bakker SJL, Voors AA et al (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31: 120–127
6. Blankenberg S, Zeller T, Saarela O et al (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121:2388–2397
7. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616
8. Olsen MH, Hansen TW, Christensen MK et al (2007) N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28:1374–1381
9. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663
10. Simmons RK, Coleman RL, Price HC et al (2009) Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovas cular disease in the EPIC-Norfolk cohort. Diabetes Care 32: 708–713
11. van der Heijden AAWA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM (2009) Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn Study. Diabetes Care 32:2094–2098
12. van Dieren S, Beulens JWJ, Kengne AP et al (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98:360–369
13. Gæde P, Hildebrandt P, Hess G, Parving HH, Pedersen O (2005) Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48:156–163
14. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH (2006) Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49:2256–2262
15. Bhalla MA, Chiang A, Epshteyn VA et al (2004) Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44:1047–1052
16. Huelsmann M, Neuhold S, Strunk G et al (2008) (2008) NT-proBNP has a nigh negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 29:2259–2264
17. Bruno G, Landi A, Barutta F et al (2013) NH2-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes. Diabetes Care 36:2677–2682
18. Hillis GS, Welsh P, Chalmers J et al (2014) The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 37:295–303
19. Price JF, Reynolds RM, Mitchell RJ et al (2008) The Edinburgh type 2 diabetes study: study protocol. BMC Endocr Disord 8:18
20. Marioni RE, Strachan MWJ, Reynolds RM et al (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 59:710–713
21. Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387
22. Clodi M, Resl M, Neuhold S et al (2012) A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol 19:944–951
23. Cook NR (2008) Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Open Clin Chem J 54:17–23
24. Resl M, Neuhold M, Riedl M et al (2011) NT-proBNP and cardiac events in older diabetic patients. Eur J Prev Cardiol 18:399–405
25. Feinkohl I, Sattar N, Welsh P et al (2012) Association of N-terminal pro-brain natriuretic peptide with cognitive function and depression in elderly people with type 2 diabetes. PLoS ONE 7:1–7
26. Feinkohl I, Keller M, Robertson CM et al (2013) Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 36:2779–2787
27. Wijsman LW, Sabayan B, van Vliet P et al (2014) N-terminal pro-brain natriuretic peptide and cognitive decline in older adults at high cardiovascular risk. Ann Neurol 76:213–222